DHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Danaher Corp (DHR) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown some positive financial growth and analysts maintain a generally positive outlook, the technical indicators, options data, and recent trading trends suggest caution. The stock is underperforming in the short term, and there is no immediate catalyst or proprietary trading signal to justify a buy at this time.
The MACD is negative and contracting, RSI is neutral at 37.13, and moving averages are converging, indicating no clear bullish momentum. The stock is trading below its pivot level of 210.273, with key support at 203.167 and resistance at 217.378. The technical indicators suggest a lack of strong upward momentum.
The company has announced a quarterly dividend, and its Q4 financials showed growth in revenue, net income, and EPS.
Congress members have sold shares recently, indicating caution. The gross margin has declined YoY, and recent news highlights weak growth and lack of confidence in acquisitions. Additionally, technical indicators and options data do not support a bullish outlook in the short term.
In Q4 2025, revenue increased by 4.59% YoY, net income rose by 10.22% YoY, and EPS grew by 12.75% YoY. However, gross margin dropped by 2.52% YoY, which could indicate cost pressures or inefficiencies.
Analysts maintain a positive outlook with multiple firms raising price targets to the $250-$275 range. The consensus is that the company is positioned for recovery in 2026, with potential upside from bioprocessing equipment and life sciences markets.
